300 related articles for article (PubMed ID: 29017950)
1. The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines.
Chang YL; Huang LC; Chen YC; Wang YW; Hueng DY; Huang SM
Int J Biochem Cell Biol; 2017 Nov; 92():155-163. PubMed ID: 29017950
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
Das CM; Aguilera D; Vasquez H; Prasad P; Zhang M; Wolff JE; Gopalakrishnan V
J Neurooncol; 2007 Nov; 85(2):159-70. PubMed ID: 17534580
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
Li LH; Zhang PR; Cai PY; Li ZC
Biomed Pharmacother; 2016 Aug; 82():161-6. PubMed ID: 27470351
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line.
Sanaei M; Kavoosi F; Roustazadeh A; Shahsavani H
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2507-2510. PubMed ID: 30256044
[TBL] [Abstract][Full Text] [Related]
7. P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells.
Bajbouj K; Mawrin C; Hartig R; Schulze-Luehrmann J; Wilisch-Neumann A; Roessner A; Schneider-Stock R
J Neurooncol; 2012 May; 107(3):503-16. PubMed ID: 22270849
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells.
Wu Y; Guo SW
Eur J Obstet Gynecol Reprod Biol; 2008 Apr; 137(2):198-203. PubMed ID: 17376583
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
Bao L; Diao H; Dong N; Su X; Wang B; Mo Q; Yu H; Wang X; Chen C
Cell Biol Toxicol; 2016 Dec; 32(6):469-482. PubMed ID: 27423454
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells.
Aztopal N; Erkisa M; Erturk E; Ulukaya E; Tokullugil AH; Ari F
Chem Biol Interact; 2018 Jan; 280():51-58. PubMed ID: 29225137
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
Condorelli F; Gnemmi I; Vallario A; Genazzani AA; Canonico PL
Br J Pharmacol; 2008 Feb; 153(4):657-68. PubMed ID: 18059320
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
Gilardini Montani MS; Granato M; Santoni C; Del Porto P; Merendino N; D'Orazi G; Faggioni A; Cirone M
Cell Oncol (Dordr); 2017 Apr; 40(2):167-180. PubMed ID: 28160167
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation.
Kawano T; Akiyama M; Agawa-Ohta M; Mikami-Terao Y; Iwase S; Yanagisawa T; Ida H; Agata N; Yamada H
Int J Oncol; 2010 Oct; 37(4):787-95. PubMed ID: 20811699
[TBL] [Abstract][Full Text] [Related]
14. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
Groh T; Hrabeta J; Khalil MA; Doktorova H; Eckschlager T; Stiborova M
Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation.
Mawatari T; Ninomiya I; Inokuchi M; Harada S; Hayashi H; Oyama K; Makino I; Nakagawara H; Miyashita T; Tajima H; Takamura H; Fushida S; Ohta T
Int J Oncol; 2015 Dec; 47(6):2073-81. PubMed ID: 26497673
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors induced differentiation and accelerated mineralization of pulp-derived cells.
Duncan HF; Smith AJ; Fleming GJ; Cooper PR
J Endod; 2012 Mar; 38(3):339-45. PubMed ID: 22341071
[TBL] [Abstract][Full Text] [Related]
17. The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells.
Zhao X; Yang W; Shi C; Ma W; Liu J; Wang Y; Jiang G
Tumour Biol; 2011 Apr; 32(2):335-46. PubMed ID: 21113745
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid in the complex therapy of malignant tumors.
Hrebackova J; Hrabeta J; Eckschlager T
Curr Drug Targets; 2010 Mar; 11(3):361-79. PubMed ID: 20214599
[TBL] [Abstract][Full Text] [Related]
19. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
20. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.
Sanchez-Gonzalez B; Yang H; Bueso-Ramos C; Hoshino K; Quintas-Cardama A; Richon VM; Garcia-Manero G
Blood; 2006 Aug; 108(4):1174-82. PubMed ID: 16675713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
